FLUVASTATIN SODIUM: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan Pharms Inc	FLUVASTATIN SODIUM	fluvastatin sodium	CAPSULE;ORAL	090595	ANDA	Mylan Pharmaceuticals Inc.	0378-8020-77	90 CAPSULE in 1 BOTTLE, PLASTIC (0378-8020-77)	2012-04-11
Mylan Pharms Inc	FLUVASTATIN SODIUM	fluvastatin sodium	CAPSULE;ORAL	090595	ANDA	Mylan Pharmaceuticals Inc.	0378-8020-93	30 CAPSULE in 1 BOTTLE, PLASTIC (0378-8020-93)	2012-04-11
Mylan Pharms Inc	FLUVASTATIN SODIUM	fluvastatin sodium	CAPSULE;ORAL	090595	ANDA	Mylan Pharmaceuticals Inc.	0378-8021-77	90 CAPSULE in 1 BOTTLE, PLASTIC (0378-8021-77)	2012-04-11
Mylan Pharms Inc	FLUVASTATIN SODIUM	fluvastatin sodium	CAPSULE;ORAL	090595	ANDA	Mylan Pharmaceuticals Inc.	0378-8021-93	30 CAPSULE in 1 BOTTLE, PLASTIC (0378-8021-93)	2012-04-11
Teva Pharms	FLUVASTATIN SODIUM	fluvastatin sodium	CAPSULE;ORAL	078407	ANDA	Teva Pharmaceuticals USA, Inc.	0093-7442-01	100 CAPSULE in 1 BOTTLE (0093-7442-01)	2012-07-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis examines the global supplier landscape for fluvastatin sodium, an active pharmaceutical ingredient (API) used in the treatment of hypercholesterolemia. It identifies key manufacturers, their production capacities, quality certifications, and geographical distribution. The data highlights the competitive dynamics and potential supply chain vulnerabilities for pharmaceutical companies relying on fluvastatin sodium.

Who are the primary global manufacturers of fluvastatin sodium API?

The production of fluvastatin sodium API is concentrated among a limited number of manufacturers, primarily located in Asia. These companies operate large-scale facilities and possess the necessary regulatory approvals to supply global markets.

Key Fluvastatin Sodium API Manufacturers:

Hetero Drugs Limited: Based in India, Hetero is a major generic pharmaceutical company with significant API manufacturing capabilities. The company is known for its broad portfolio of APIs and has a strong presence in regulated markets.
Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical firm, Dr. Reddy's offers a diverse range of APIs, including those for cardiovascular drugs. Their manufacturing sites adhere to stringent quality standards.
Sun Pharmaceutical Industries Ltd.: Sun Pharma, also headquartered in India, is one of the largest generic pharmaceutical companies globally. They produce a wide array of APIs and have a robust supply chain infrastructure.
Takeda Pharmaceutical Company Limited: While Takeda is a global pharmaceutical giant, their API manufacturing for fluvastatin sodium may be more targeted or through subsidiary operations. Takeda has historically been involved in the development and manufacturing of statins.
Novartis AG: Similar to Takeda, Novartis, a Swiss multinational, may produce fluvastatin sodium API for its internal use or through specific manufacturing agreements. Their focus often lies on innovative drug development, but they maintain substantial API production capacity.
Zhejiang Huahai Pharmaceutical Co., Ltd.: A leading Chinese pharmaceutical company, Huahai is a significant supplier of APIs to the global market. They are recognized for their extensive manufacturing scale and compliance with international regulatory standards.
Lupin Limited: Based in India, Lupin is a global pharmaceutical company with a strong focus on generics. They manufacture a variety of APIs and have established a significant global footprint.

These manufacturers represent a substantial portion of the global fluvastatin sodium API supply. Their production capacities, quality control systems, and regulatory compliance are critical factors for pharmaceutical companies sourcing this API.

What are the typical production capacities and scales of these suppliers?

Production capacities for fluvastatin sodium API can vary significantly among manufacturers. Companies with dedicated large-scale facilities can produce metric tons of the API annually. For example, major Indian and Chinese API manufacturers typically operate plants capable of producing hundreds of metric tons of various APIs per year, with fluvastatin sodium being a component of this output.

While precise, publicly disclosed capacities for fluvastatin sodium alone are often proprietary, an indication of scale can be inferred from their overall API production. Leading manufacturers like Hetero Drugs, Dr. Reddy's Laboratories, and Zhejiang Huahai Pharmaceutical are known to operate multi-tonnage facilities for common generic APIs.

Factors Influencing Production Scale:

Market Demand: The overall demand for fluvastatin sodium in generic drug formulations directly impacts production volumes.
Facility Infrastructure: The size and number of reactors, purification systems, and drying equipment dictate the potential output.
Operational Efficiency: Optimization of synthesis routes and process controls contribute to higher yields and throughput.
Regulatory Approvals: Capacity expansion is often tied to obtaining regulatory clearances for increased production volumes.

A typical large-scale API manufacturing plant can produce upwards of 50-100 metric tons of a specific high-volume API per year. Fluvastatin sodium, as a mature generic drug, likely falls within this range for leading suppliers.

Which quality certifications and regulatory approvals are essential for fluvastatin sodium API suppliers?

Suppliers of fluvastatin sodium API must meet stringent quality and regulatory standards to be eligible for sale in major pharmaceutical markets. These certifications ensure the API's purity, potency, and safety.

Key Quality Certifications and Regulatory Approvals:

Current Good Manufacturing Practices (cGMP): Compliance with cGMP guidelines, as established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is mandatory. This ensures consistent production and quality control.
Drug Master Files (DMFs): Manufacturers must file DMFs with regulatory authorities (e.g., FDA, Health Canada). A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review the API's quality without disclosing proprietary information to the drug product manufacturer.
CEP/COS (Certificate of Suitability to the Monographs of the European Pharmacopoeia): This certificate, issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), demonstrates that an API complies with the requirements of the European Pharmacopoeia. It is essential for market access in Europe and many other countries that recognize EDQM standards.
WHO GMP Certification: Certification from the World Health Organization (WHO) is often required for supplying APIs to developing countries and is indicative of robust quality management systems.
Site Inspections and Audits: Regular inspections by regulatory agencies (FDA, EMA) and audits by drug product manufacturers are critical. Successful completion of these signifies adherence to quality standards.
ISO Certifications (e.g., ISO 9001): While not specific to pharmaceutical APIs, ISO 9001 certification demonstrates a commitment to quality management systems across the organization.

Companies like Hetero Drugs, Dr. Reddy's Laboratories, Sun Pharma, and Zhejiang Huahai Pharmaceutical routinely undergo FDA and EMA inspections and maintain active DMFs and CEPs for their key APIs, including fluvastatin sodium.

What is the geographical distribution of fluvastatin sodium API manufacturing?

The manufacturing of fluvastatin sodium API is geographically concentrated, with India and China being the dominant production hubs.

Primary Manufacturing Regions:

India: Home to many of the world's largest API manufacturers, India benefits from a skilled workforce, a well-established pharmaceutical ecosystem, and cost-effective production. Companies like Hetero, Dr. Reddy's, and Sun Pharma have extensive API manufacturing facilities here.
China: China is another significant producer of APIs globally, including fluvastatin sodium. Zhejiang Huahai Pharmaceutical is a prime example of a major Chinese API supplier. The country's large-scale chemical manufacturing capabilities and competitive pricing make it a key player.
Europe: While Europe has historically been a strong pharmaceutical manufacturing base, the production of generic APIs like fluvastatin sodium has largely shifted to Asia due to cost pressures. However, some European companies, like Takeda and Novartis, may retain specific manufacturing capabilities or engage in contract manufacturing within the region.

Factors Driving Geographical Concentration:

Cost of Production: Lower labor and operational costs in India and China enable competitive API pricing.
Regulatory Expertise: Manufacturers in these regions have developed significant expertise in navigating global regulatory requirements, including DMF filings and cGMP compliance.
Infrastructure Development: Significant investment in pharmaceutical manufacturing infrastructure has occurred in these countries over the past few decades.
Supply Chain Integration: The presence of a strong ecosystem of raw material suppliers and supporting industries in these regions further enhances their manufacturing advantage.

This concentration means that global pharmaceutical companies often rely on a limited number of suppliers from these two countries for their fluvastatin sodium API needs.

What are the potential supply chain risks associated with fluvastatin sodium API sourcing?

The concentrated geographical distribution and the nature of API manufacturing present several potential supply chain risks for fluvastatin sodium.

Key Supply Chain Risks:

Geopolitical Instability and Trade Policies: Tensions or trade disputes between major sourcing countries (e.g., China, India) and major consumer markets can lead to import restrictions, tariffs, or disruptions. Any significant policy changes in these regions could impact availability and cost.
Regulatory Enforcement Actions: Stricter regulatory enforcement, such as FDA or EMA import alerts or facility shutdowns due to cGMP violations, can immediately halt the supply of API from a particular manufacturer. Recent years have seen increased scrutiny on API facilities in both India and China.
Natural Disasters and Environmental Incidents: Manufacturing facilities are susceptible to disruptions from earthquakes, floods, or other natural calamities. Environmental regulations are also becoming stricter, and non-compliance can lead to production stoppages.
Quality Control Failures: Any lapse in quality control by a major supplier can lead to product recalls, batch rejections, and subsequent supply shortages. The challenge of maintaining consistent quality across large-scale production is significant.
Raw Material Availability: The synthesis of fluvastatin sodium relies on specific chemical intermediates. Disruptions in the supply of these raw materials, often sourced from different regions, can impact the API manufacturer's ability to produce fluvastatin sodium.
Intellectual Property (IP) Disputes: While fluvastatin sodium is a generic drug, ongoing IP considerations or patent challenges related to its manufacturing process or specific polymorphic forms could indirectly affect supply or create market uncertainty.
Concentration Risk: Relying on a few key suppliers, particularly those concentrated in specific geographies, creates a vulnerability. If one or two major suppliers face production issues, it can significantly impact the global market supply. For example, a significant portion of global fluvastatin sodium API may be produced by just a handful of companies.
Logistical Challenges: Transportation disruptions, port congestion, or increased shipping costs can impact the timely delivery of API to drug product manufacturers worldwide.

Pharmaceutical companies are increasingly adopting strategies such as multi-sourcing, building strategic partnerships, and maintaining higher inventory levels to mitigate these risks.

How do different regulatory agencies (e.g., FDA, EMA) approach the oversight of fluvastatin sodium API manufacturing?

Regulatory agencies like the FDA and EMA maintain robust oversight mechanisms to ensure the quality, safety, and efficacy of APIs, including fluvastatin sodium. Their approach is multifaceted, encompassing pre-market review, post-market surveillance, and facility inspections.

FDA Oversight:

Drug Master Files (DMFs): The FDA reviews DMFs submitted by API manufacturers. While the DMF itself is confidential, the FDA uses the information within to assess the API's manufacturing process, quality controls, and stability when reviewing a drug product application that relies on that API.
cGMP Inspections: The FDA conducts routine and For-Cause inspections of API manufacturing facilities worldwide. These inspections verify compliance with U.S. cGMP regulations (21 CFR Part 210 and 211). Non-compliance can result in warning letters, import alerts, or other enforcement actions.
ANDA Review: For generic drug applications (Abbreviated New Drug Applications or ANDAs), the FDA scrutinizes the API source, ensuring it meets compendial standards and that the manufacturer has a satisfactory cGMP history.
Post-Market Surveillance: The FDA monitors adverse event reports and other data to identify potential quality issues with marketed drugs, which can trace back to API quality.

EMA Oversight:

CEP/COS: The EDQM, an arm of the Council of Europe, issues Certificates of Suitability (CEP), which the EMA recognizes. A CEP confirms that an API complies with the European Pharmacopoeia monograph.
GMP Inspections: The EMA, through its member states' national competent authorities, conducts GMP inspections of API manufacturing sites. These inspections verify compliance with EU GMP guidelines.
Marketing Authorisation Applications (MAA): For MAAs, the EMA requires detailed information on the API, including its manufacturing process, specifications, and the API manufacturer's quality system. This includes details from the DMF or CEP.
European Pharmacopoeia: The EMA relies on monographs in the European Pharmacopoeia for API quality standards.

Common Themes in Oversight:

Emphasis on Quality Management Systems: Both agencies prioritize a robust and effective Quality Management System (QMS) at the API manufacturing site.
Traceability and Documentation: Strict requirements for batch records, analytical testing, and traceability of materials are enforced.
Risk-Based Approach: Regulators often employ a risk-based approach, prioritizing inspections and reviews based on the criticality of the API and the manufacturer's compliance history.
International Collaboration: Agencies like the FDA and EMA engage in mutual recognition agreements and data sharing to enhance global oversight efficiency.

The rigor of these regulatory reviews and inspections directly influences the reliability and market access of fluvastatin sodium API suppliers.

What are the key market trends impacting fluvastatin sodium API suppliers?

Several market trends are shaping the landscape for fluvastatin sodium API suppliers, influencing demand, pricing, and strategic decisions.

Key Market Trends:

Increasing Genericization: As patents expire on branded statins, the demand for generic fluvastatin sodium API continues to grow, particularly in emerging markets. This sustains demand for established API manufacturers.
Price Pressure and Competition: The generic API market is highly competitive, leading to significant price pressure. Suppliers must optimize their manufacturing processes to remain cost-competitive while maintaining high quality. This often favors large-scale, efficient producers.
Consolidation in the Pharmaceutical Industry: Mergers and acquisitions among drug product manufacturers can lead to changes in sourcing strategies and supplier relationships. Larger drug companies may consolidate their API sourcing to fewer, more strategic partners.
Supply Chain Diversification and Resilience: Following global supply chain disruptions, pharmaceutical companies are increasingly seeking to diversify their API sources and enhance supply chain resilience. This might create opportunities for suppliers in new geographies or those demonstrating superior risk management capabilities. However, the established dominance of India and China remains a significant factor.
Increased Regulatory Scrutiny: Heightened regulatory expectations regarding quality, data integrity, and impurity profiling (e.g., nitrosamines) mean that API suppliers must continually invest in analytical capabilities and quality systems to meet evolving standards. This can create barriers to entry for smaller or less sophisticated manufacturers.
Focus on Impurity Control: Regulatory bodies have intensified their focus on controlling impurities, including genotoxic impurities. Suppliers need to have sophisticated analytical methods and process controls to detect and limit these substances in their fluvastatin sodium API.
Technological Advancements in Manufacturing: Innovations in continuous manufacturing, process analytical technology (PAT), and automation can improve efficiency, yield, and quality control, offering competitive advantages to suppliers that adopt them.

These trends necessitate that fluvastatin sodium API suppliers remain agile, invest in quality and efficiency, and proactively manage supply chain risks to maintain their market position.

What is the future outlook for fluvastatin sodium API suppliers?

The future outlook for fluvastatin sodium API suppliers is characterized by sustained demand driven by the generic market, coupled with ongoing challenges related to competition, regulatory compliance, and supply chain security.

Future Outlook:

Stable to Moderate Growth in Demand: The continued prevalence of hypercholesterolemia and the affordability of generic statins ensure a stable demand for fluvastatin sodium API. Growth will likely be moderate, driven by increasing healthcare access in emerging economies.
Intensifying Competition and Margin Squeeze: The generic API market will remain highly competitive. Suppliers will face continued pressure on pricing, necessitating operational excellence and cost optimization. Manufacturers with strong economies of scale and efficient processes will be best positioned.
Continued Dominance of Asian Manufacturers: India and China are expected to maintain their leading roles in fluvastatin sodium API production due to cost advantages and established infrastructure. However, global supply chain concerns may drive some efforts towards regional diversification or dual-sourcing strategies by drug product manufacturers.
Evolving Regulatory Landscape: Suppliers must remain vigilant regarding evolving regulatory expectations concerning impurity control, data integrity, and advanced manufacturing techniques. Compliance will be a critical differentiator and a prerequisite for market access.
Strategic Importance of Quality and Reliability: In an environment of increasing supply chain awareness, suppliers who can consistently demonstrate high-quality products, robust supply chain management, and proactive risk mitigation will command a premium and secure long-term partnerships.
Potential for Consolidation: The competitive pressures and the need for significant investment in compliance and technology may lead to further consolidation within the API manufacturing sector. Smaller players may be acquired or exit the market.

The fluvastatin sodium API market will continue to be a vital segment of the pharmaceutical supply chain, demanding strategic focus on quality, cost-efficiency, and resilient supply chain management from its key players.

Key Takeaways

Fluvastatin sodium API production is concentrated among a few key manufacturers, primarily in India and China.
Essential quality certifications include cGMP, DMFs, and CEPs, with stringent oversight from regulatory bodies like the FDA and EMA.
Supply chain risks are significant, stemming from geopolitical factors, regulatory enforcement, quality control issues, and raw material dependency.
Market trends such as increasing genericization and intense price competition necessitate operational efficiency and robust quality systems from suppliers.
The future outlook suggests stable demand but ongoing challenges in competition and regulatory compliance, favoring suppliers with strong quality and supply chain management.

Frequently Asked Questions

1. What is the typical lead time for ordering fluvastatin sodium API from a major supplier?

Typical lead times for fluvastatin sodium API can range from 8 to 16 weeks, depending on the supplier's existing inventory, production schedule, and the quantity ordered. However, significant disruptions or custom manufacturing requirements can extend this period.

2. How does the price of fluvastatin sodium API vary between suppliers?

Price variations are influenced by production scale, cost of raw materials, quality certifications, and the supplier's geographical location and associated operational costs. Manufacturers with higher regulatory compliance and a stronger track record in regulated markets may command slightly higher prices, while large-volume producers in Asia often offer more competitive rates.

3. Are there any significant impurities that fluvastatin sodium API manufacturers must rigorously control?

Yes, manufacturers must control process-related impurities and potential degradation products. Regulatory agencies are particularly focused on controlling specific impurities, such as nitrosamine impurities, and any other potentially genotoxic substances to ensure patient safety. Detailed impurity profiles are a critical part of regulatory filings.

4. Can a drug product manufacturer switch fluvastatin sodium API suppliers if issues arise with the current supplier?

Yes, switching API suppliers is possible but requires a formal regulatory process. Drug product manufacturers must submit variations or amendments to their marketing authorizations, demonstrating that the new API source meets all quality specifications and that bioequivalence is maintained if necessary. This process can be time-consuming.

5. What is the role of contract manufacturing organizations (CMOs) in fluvastatin sodium API production?

While major pharmaceutical companies often have in-house API manufacturing capabilities, some may utilize CMOs for specific synthesis steps or for the entire fluvastatin sodium API production. CMOs can offer specialized expertise, flexible capacity, and cost advantages, but require rigorous supplier qualification by the pharmaceutical company.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from www.fda.gov (General information about DMFs and their purpose).

[2] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from www.edqm.eu (Information on CEPs and their role in API quality).

[3] World Health Organization. (n.d.). WHO GMP Certification (Specific details on WHO GMP requirements and certification processes).

[4] United States Pharmacopeia. (n.d.). Fluvastatin Sodium Monograph. (Information on compendial standards and quality specifications for fluvastatin sodium).

[5] European Medicines Agency. (n.d.). Active substances (APIs). Retrieved from www.ema.europa.eu (General information on EMA's approach to API oversight).

Suppliers and packagers for generic pharmaceutical drug: FLUVASTATIN SODIUM